Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
|Articles|October 25, 2021
Daily OTC Pearl: Azo (Phenazopyridine) for Urinary Tract Health
Author(s)Saro Arakelians, PharmD
Azo treats urinary pain, burning, urgency, and frequency associated with urinary tract infections.
Advertisement
OTC/Lifestyle Pearl of the Day: Azo (Phenazopyridine)
Indication: Relief from urinary pain, burning, urgency, and frequency associated with urinary tract infections.
Insight:
- Active ingredient in each tablet is phenazopyridine hydrochloride 97.5 mg.
- Dosing: Adults and children 12 years of age or older take 2 tablets 3 times daily, with or after meals, as needed for up to 2 days. Take with a full glass of water.
- Dosage forms: 95 mg, 97.2 mg, 100 mg, 200 mg.
- Directions to use: This medication should be taken by mouth, usually 3 times daily after meals or as directed by a physician.
- Adverse effects: Little or no urinating, swelling, confusion, fever, pale or yellowish skin, blue or purple appearance, headache, and dizziness.
- Do not use this medication while wearing soft contact lenses. Phenazopyridine can permanently discolor soft contact lenses.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
Pneumonic Plague: Symptoms, Antibiotics, and Current US Risk
3
Inside the New Consensus Recommendations for Acute Stroke Care
4
The Coding Gap Nobody Prices In: Why New Specialty Drugs Launch Reimbursement-Blind
5